article · Scientific Reports
Atherosclerotic cardiovascular diseases are a major cause of death, particularly among individuals living with type 2 diabetes. A clinical trial investigated whether adding curcumin to standard treatment improves health outcomes in seventy-two diabetic patients with elevated cardiovascular risk. Participants received either five hundred milligrams of a commercial turmeric curcumin supplement three times daily alongside conventional therapy, or conventional therapy alone. The supplemented group experienced significant reductions in systolic and diastolic blood pressure, lower low-density lipoprotein cholesterol, decreased inflammatory and oxidative markers, and higher high-density lipoprotein cholesterol. Overall cardiovascular risk scores improved. The supplement did not significantly alter blood glucose, long-term glycaemic control, body mass index, heart rate, or total cholesterol. Reported adverse effects were mild, showing the intervention was generally well tolerated.
Managing cardiovascular complications in people with type 2 diabetes remains a major global healthcare challenge. These findings show that a widely available natural supplement can safely support standard medical care by lowering blood pressure, improving cholesterol markers, and reducing inflammation, potentially offering a low-risk complementary approach to lowering cardiovascular disease risk.
This research evaluates a commercial supplement, Turmeric curcumin, in an applied clinical setting involving human patients. It points to immediate applications in nutraceuticals and complementary therapies for healthcare providers managing diabetic cardiovascular risks. Because the intervention relies on an existing, tested formulation, the pathway to real-world clinical or dietary adoption is near-market, provided local regulatory requirements for health supplements are met.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Atherosclerotic cardiovascular diseases (ASCVD) significantly contribute to global mortality, especially in type 2 diabetes mellitus (T2DM), necessitating effective preventive strategies. Curcumin is proposed to lower blood pressure, glucose level, and improve lipid profiles as an adjunctive treatment. The study aimed to assess the safety and efficacy of Curcumin supplementation on clinical outcomes and ASCVD risk of T2DM patients. Seventy-two diabetic patients with an ASCVD risk score of ≥ 5% were randomly assigned to Curcumin group (500 mg Turmeric curcumin ® thrice daily + conventional therapy) or Control group (conventional therapy only). Curcumin significantly reduced SBP and DBP ( P ≤ 0.001 and P = 0.020, respectively) and improved ASCVD risk classification ( P = 0.004). LDL-C ( P = 0.024), TNF-α ( P = 0.044), and MDA ( P = 0.028) levels decreased, while HDL-C increased ( P = 0.024) versus control. No significant differences were found between groups regarding HbA1c, FBG, TC or TG ( P > 0.05). Mild adverse effects were reported, including nausea (13.9%), headache (11.1%), yellow stool (11.1%), and diarrhea (5.6%). It is concluded that Curcumin improves ASCVD risk classification, lowers SBP, DBP, LDL-C, TNF-alpha, and MDA, increases HDL-C, and is well tolerated with minor adverse effects, without impacting on BMI, HR, HbA1c, FBG, TC, or TG.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1038/s41598-025-09783-5
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
